SwitzerlandSwitzerland

Biotech partnering and the other IP

07.03.2012



Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their intellectual property all on their own. They need another kind of IP – Intelligent Partnerships, especially in the expanding monoclonal antibodies market.

Since the beginning of the economic crisis, the bio­technology sector has had to endure a lot of negative news, even suggestions that the industry as a whole could collapse. Whilst overly exaggerated, the current viewpoint is certainly grave. But let’s look at the abbreviation of IP in another way: Intelligent Partnerships! Below are a couple of examples of this essential area that we consider important to the future of the biotech industry.
IP between academia and industry is key to the sustainability of the sector. The raw material for new start-up ventures is mostly a transfer from universities into industries. Understanding how to manage the interactions between the public partner (which most universities are) and the private sector is an indispensable ability for future development of the company. Evaluating science amongst peers becomes more important as the industry grows more global.
IP requires smart money!
IP often requires good, experienced and well-connected investors. Only if smart money finds its way into the venture can you expect solid development of results and milestone achievements. The prudent investor base isn’t only involved in the Life Science and Biotechnology sectors. If investors see better (or safer) future exits for their money, they will turn away from our risky but highly-rewarding industry and invest in other areas.
IP is also necessary with a view to fostering increased respect for the research community. Its members produce innovation, which leads to new products, new cures, new production methods, new companies and to more jobs. The service sector depends a lot on a pipeline of new ideas that can be turned into products with commercial value. In the past, society respected researchers and engineers much more than they do today. We should alter that current perception as quickly as possible and motivate young talents to look for professional success in science and engineering.
IP works well in countries where major government and industry funding is available. These entities invest and manage start-up funds, and by doing so create a pipeline of new companies. Critics might say that too much state aid is not good for the sector, but managed well, rewards are higher than initial investments. After all, a larger and improved work force is the goal of any economy.
IP needs cluster management
Not many industries are better equipped to be grouped into clusters based on Porter’s theory of building competitive advantages. Hotbeds of biotech can be found in countries all over the world, and they compete with one another. If that competitive spirit leads to better science and economic output it’s all well and good, but if it becomes an obstacle for sustainable development then it’s better to change strategies. The size of a country also determines the number of clusters.
Related to the IP of cluster management is the fact that transatlantic collaborations in the public sector need to be improved. For decades, academic institutions have worked with peers all over the world, but funding agencies still hold off on investments. The European Union’s FP-programmes are steps in the right direction, but the bureaucracy for each programme remains high. Partnering events like the BIO-Europe Spring are also good platforms for starting sustainable relationships.

Stimulate IP!

Last but not least, IP in creating an improved and better image for biotechnology is a must. Biotech is a far-reaching instrument for providing good solutions to the world’s most pressing issues, but we all need to use its tools wisely and have patience. Intelligent Partnerships can only grow if we are all taking part.

SwitzerlandSwitzerland

10.11.2011

Alschwil - Actelion Ltd. gets a badly needed injection of fresh capital. Under the guidance of the two biggest Swiss banks, UBS and Credit Suisse, the Swiss biopharmaceutical company takes up €171 million agreeing to pay a 4,875%...

SwitzerlandSwitzerland

18.10.2011

Basel/San Diego –Swiss drug company Roche has announced it is buying biotech-company Anadys Pharmaceuticals for US$230 million. Under the terms of the merger agreement, Roche will commence an all cash tender offer for all...

Germany, SwitzerlandSwitzerland

12.10.2011

The Swiss technology transfer organisation Unitectra is the winner of the European Biotechnica Award 2011. The specialist for technology transfer received the award from hands of Lower Saxony's Minister for Economy Jörg Bode. The...

SwitzerlandSwitzerland

01.10.2011

Liestal – Swiss Santhera AG has announced strict savings measures. Out of a total of 21 employees, almost every second is now slated to be sacked. The biotech firm is closing its department of preclinical development and scaling...

SwitzerlandSwitzerland

01.10.2011

Schlieren – Swiss biotechnology company Cytos AG has finally devised a plan to help its lead candidate into Phase II, but to achieve it, the cash-strapped company is having to slash its workforce by a whopping 85%. To ensure the...

SwitzerlandSwitzerland

01.10.2011

Geneva – Swiss biotech Addex Pharmaceuticals AG has regained all rights to its metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator (PAM) programme from Merck&Co, (known as MSD outside the United States and...

SwitzerlandSwitzerland

01.10.2011

Hamburg – When the compound EVT302 failed proof-of-concept testing in the spring of 2009, investors began backing away from Evotec AG shares. Now the selective MAO-B inhibitor is back, and has powered a leap in the company’s...

SwitzerlandSwitzerland

15.09.2011

Zurich – The FDA has posted a manufacturing warning to Lonza following an inspection of the firm's microbial production site for Eisai’s cancer drug Ontak in Hopkinton. However, analysts at Vontobel said that the impact of the...

SwitzerlandSwitzerland

30.08.2011

Schlieren - Swiss biotechnology company Cytos has devised a plan to get its lead candidate into Phase II. To achieve this, the cash strapped company will slash its workforce, as previously announced, by 85%. To ensure the...

SwitzerlandSwitzerland

22.08.2011

Liestal – Swiss Santhera Pharmaceuticals and researchers from Newcastle University have published the results from a pivotal clinical trial demonstrating that the firm’s synthetic coenzyme Q10 derivative idebenone significantly...

Displaying results 21 to 30 out of 276

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-switzerland/browse/2/article/biotech-partnering-and-the-other-ip.html

Print Magazine

Product of the week

Products

Events

All Events

Stock list

All quotes

TOP

  • FORMYCON9.74 EUR9.44%
  • CYTOS0.29 CHF3.57%
  • BAYER118.00 EUR3.42%

FLOP

  • MAGFORCE6.12 EUR-2.55%
  • SARTORIUS95.00 EUR-2.06%
  • ADDEX3.01 CHF-1.95%

TOP

  • CYTOS0.29 CHF81.2%
  • EPIGENOMICS5.25 EUR48.7%
  • STRATEC BIOMEDICAL48.65 EUR25.2%

FLOP

  • BIOFRONTERA2.53 EUR-12.8%
  • ADDEX3.01 CHF-8.8%
  • CO.DON2.53 EUR-8.0%

TOP

  • SANTHERA91.30 CHF2709.2%
  • CO.DON2.53 EUR153.0%
  • BB BIOTECH182.60 EUR63.0%

FLOP

  • CYTOS0.29 CHF-91.4%
  • 4SC0.94 EUR-46.3%
  • MOLOGEN7.39 EUR-42.0%

No liability assumed, Date: 24.11.2014

Current issue

All issues